Caption Management’s Cymabay Therapeutics CBAY Stock Holding History

Caption Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-44,300	Closed	-$1.05M	–	1771
2023 Q4	$1.05M	Sell	44,300 -446,300	-91%	-$7.95M	0.01%	795
2023 Q3	$7.31M	Buy	+490,600	New	+$6.5M	0.11%	226
2023 Q2	–	Sell	-120,000	Closed	-$1.05M	–	1479
2023 Q1	$1.05M	Buy	120,000 +25,000	+26%	+$200K	0.02%	626
2022 Q4	$596K	Buy	95,000 +45,000	+90%	+$171K	0.01%	881
2022 Q3	$174K	Sell	50,000 -5,000	-9%	-$18K	﹤0.01%	1266
2022 Q2	$162K	Hold	55,000	–	–	﹤0.01%	1260
2022 Q1	$172K	Buy	+55,000	New	+$173K	﹤0.01%	1284
2020 Q3	–	Sell	-90,000	Closed	-$315K	–	1320
2020 Q2	$315K	Buy	+90,000	New	+$260K	0.01%	746

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's CBAY Position: Q3 2022 in Review

Caption Management sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 30,000 shares — an estimated $108K sold.

Caption Management first reported a position in CBAY in Q2 2019 and held it in 4 quarters. The position peaked at $314K in Q2 2020. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

Caption Management reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
Caption Management sold 30,000 Cymabay Therapeutics shares in Q3 2022, an estimated $108K.
Caption Management first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 4 quarters.
Caption Management's Cymabay Therapeutics position peaked at $314K in Q2 2020.
100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.